Search Within

Rona Denit Yaeger

Formats
  1. Meeting Abstract (166)
  2. Journal Article (143)
  3. Review (7)
  4. Editorial (6)
  5. Research Letter (4)
  6. Book Section (1)
  7. Correspondence (1)
  8. Guidelines (1)
Groups
  1. Department of Medicine (329)
  2. Gastrointestinal Oncology Service (329)
  3. Solid Tumor Oncology Division (329)
  4. Center for Pancreatic Cancer Research (136)
  5. GSK Faculty (134)
  6. Department of Pathology and Laboratory Medicine (125)

More Groups

People
  1. Andrea Cercek Hanjis (95)
  2. Leonard Saltz (81)
  3. Jinru Shia (76)
  4. Martin Weiser (64)
  5. Zsofia Stadler (62)
  6. Julio Garcia Aguilar (61)

More People

Years
  1. 2025 (29)
  2. 2024 (41)
  3. 2023 (37)
  4. 2022 (39)
  5. 2021 (36)
  6. 2020 (28)

More Years

Publications
  1. Journal of Clinical Oncology (101)
  2. Annals of Oncology (37)
  3. Clinical Cancer Research (17)
  4. Cancer Research (15)
  5. Cancer Discovery (14)
  6. Nature Medicine (9)

More Publications

Publishers
  1. American Society of Clinical Oncology (111)
  2. American Association for Cancer Research (51)
  3. Oxford University Press (48)
  4. Nature Publishing Group (26)
  5. Elsevier Inc. (19)
  6. Springer (10)

More Publishers

Results (329)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study
    Meeting Abstract

    Desai, J.; Kopetz, S.; Murphy, D. A.; Pu, J.; Ciardiello, F.; Grothey, A.; Van Cutsem, E.; Singh Wasan, H.; Yaeger, R.; Yoshino, T.; more...
    Asia-Pacific Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Type of recurrence is associated with disease-free survival after salvage surgery for locally recurrent rectal cancer
    Journal Article

    Jimenez-Rodriguez, R. M.; Yuval, J. B.; Sauve, C. E. G.; Wasserman, I.; Aggarwal, P.; Romesser, P. B.; Crane, C. H.; Yaeger, R.; Cercek, A.; Guillem, J. G.; more...
    International Journal of Colorectal Disease (2021)

    Fulltext@MSK | Save
  • Early TP53 alterations shape gastric and esophageal cancer development
    Review

    Sahgal, P.; Huffman, B. M.; Patil, D. T.; Chatila, W. K.; Yaeger, R.; Cleary, J. M.; Sethi, N. S.
    Cancers (2021)

    Fulltext@MSK | Save
  • KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation
    Meeting Abstract

    Weiss, J.; Yaeger, R. D.; Johnson, M. L.; Spira, A.; Klempner, S. J.; Barve, M. A.; Christensen, J. G.; Chi, A.; Der-Torossian, H.; Velastegui, K.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC)
    Meeting Abstract

    Fakih, M.; Falchook, G. S.; Hong, D. S.; Yaeger, R. D.; Chan, E.; Mather, O.; Cardona, P.; Dai, T.; Strickler, J.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • HSF1 promotes inflammation induced tumor development through ECM remodeling
    Meeting Abstract

    Galibov, O. L.; Lavon, H.; Wassermann-Dozorets, R.; Pevsner-Fischer, M.; Mayer, S.; Wershof, E.; Stein, Y.; Brown, L. E.; Zhang, W.; Friedman, G.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Colibactin mutation signatures are associated with a distinct colorectal cancer clinicopathologic phenotype
    Meeting Abstract

    Lumish, M. A.; Luthra, A.; Asawa, S.; Cambuli, F.; Donoghue, M.; Woo, H. J.; Cercek, A.; Yaeger, R.; Shia, J.; Sanchez-Vega, F.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Response to total neoadjuvant therapy and survival in patients with early onset locally advanced rectal cancer
    Meeting Abstract

    Lumish, M.; Do, E.; Gonen, M.; Yaeger, R.; Weiser, M.; Cercek, A.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer
    Meeting Abstract

    Van Cutsem, E.; Taieb, J.; Yaeger, R.; Yoshino, T.; Maiello, E.; Elez, E.; Dekervel, J.; Ross, P.; Ruiz Casado, A.; Graham, J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Effect of prior bevacizumab treatment in BRAF V600Emutant metastatic colorectal cancer: Overall survival with encorafenib + cetuximab +/- binimetinib in BEACON CRC
    Meeting Abstract

    Aderka, D.; Kopetz, S.; Grothey, A.; Van Cutsem, E.; Yaeger, R.; Wasan, H.; Yoshino, T.; Desai, J.; Ciardiello, F.; Golden, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save